COVID-19: A Message from Our CEO
"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL LimitedRead Our Letter to Patients
CSL’s New Chief Scientific Officer
Dr. Andrew Nash has a lot on his plate, but he really wants to see your latest data.
COVID-19 and School
Right now, there are more questions than answers. Three experts offer advice on coping with unknowns.
Potential COVID-19 Treatment Takes Shape
Production under way for clinical testing at CSL Behring sites around the world.
Gratitude for Plasma Donors in Five Quotes
Last week, top U.S. officials, including Dr. Anthony Fauci, thanked those who donate plasma after recovering from COVID-19.
Convalescent Plasma and Hyperimmune Globulin
Find out 5 key differences between these two approaches to treating COVID-19.
Prepare, Perform, Prevail
Get 5 Lessons for navigating the rare disease Alpha 1 from a pioneering fighter pilot.
Disorder Channel Brings Rare Disease Stories to TV
Film festival founders create streaming channel for rare disease community.
Watch Online: CSL CEO at a White House Roundtable
Perreault made the case for a plasma-based hyperimmune to treat COVID-19.
Ironman Athlete Takes On Primary Immunodeficiency
The race has changed, but marathoner Stacy Ahearn is still pushing ahead following a rare disease diagnosis at age 40.